LUX-Lung 3 Clinical Trial Infographic

Boehringer Ingelheim

A randomised, open-label, Phase III study of afatinib* versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (EGFR mutation-positive first-line).

*Afatinib (compound code BIBW 2992) is an investigational compound. Its safety and efficacy has not yet been fully established.

Items: 10

LUX Lung 3 clinical cancer trial

Summary of LUX Lung 1 clinical trial

EGFR dysregulation and inhibition

BIBW 2992 cancer treatment data presented at ASCO

Mode of action afatinib* slide kit

ErbB Family Blockade and Afatinib Infographic

Clinical trials data suggests promising overall survival and progression-free survival in patients with NSCLC using BIBF 1120*

HER2 Mode of Action

Angiokinase inhibitors in lung cancer

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on